Skip to main content
Houston Shock Symposium Main banner
Back

Marvin A. Konstam, MD

Chief Physician Executive Emeritus, the CardioVascular Center; Professor of Medicine and Radiology.
The CardioVascular Center at Tufts Medical Center, Tufts University School of Medicine
Tufts University School of Medicine
Boston, Massachusetts, United States

Marvin A. Konstam is Professor of Medicine and Radiology at Tufts University School of Medicine, where he is recipient of the Distinguished Faculty Award, and Chief Physician Executive Emeritus of the CardioVascular Center of Tufts Medical Center. He is board certified in Advanced Heart Failure and Transplant Cardiology, Cardiovascular Disease, Internal Medicine, and Radiology.

Dr. Konstam is an internationally known expert with over 350 published articles, mostly on topics of ventricular remodeling, heart failure therapeutics and diagnostics, and quality of care. He has served as Senior Advisor in Cardiovascular Diseases to the National Heart Lung and Blood Institute; on multiple advisory panels for the US Food and Drug Administration – presently an active member of the Cardiovascular and-Renal Advisory Panel of the Center for Drug Evaluation and Research; and on the Medicare Evidence Development and Coverage Advisory Committee of the Centers for Medicare and Medicaid Services.

Dr. Konstam previously served as President of the Heart Failure Society of America (HFSA), as President of the Association of Professors of Cardiologists, as Chair of the Leadership Council of the Academic Cardiology Section of the American College of Cardiology, and member of its Health Affairs Committee.

Dr. Konstam serves as a Founder and Chief Scientific Officer of Cardiovascular Clinical Sciences, a CV-focused contract research organization and has served as Chief Medical Officer of a start-up CV bio-technology firm.

Dr. Konstam was awarded the Lifetime Achievement Award by the HFSA and the Paul Dudley White Award by the Massachusetts American Heart Association

Disclosure(s): Alleviant: Consultant/Advisory Board (Ongoing); Alnylam: Consultant/Advisory Board (Ongoing); Boehringer-Ingelheim: Consultant/Advisory Board (Ongoing); Cardurian: Consultant/Advisory Board (Ongoing); LivaNova: Consultant/Advisory Board (Terminated, December 31, 2024), Research Grant or Support (Terminated, December 31, 2024); SC Pharma: Consultant/Advisory Board (Ongoing), Research Grant or Support (Ongoing); Vicardia: Consultant/Advisory Board (Ongoing)

Presentation(s):

Email Marvin